Kornimate/medical-research-clean huggingface dataset:
molecular diagnosis of allergic contact dermatitis (smeca).

Conditions: Eczema; Allergic Contact Eczema Nos

Summary: allergic contact dermatitis (acd) is a common inflammatory skin disease, which represents a major public health issue in industrialized countries. acd is induced by repeated contact of individuals with environmental chemicals and is characterized by a delayed type iv hypersensitivity response with skin inflammation mediated by allergen-specific t cells in sensitized individuals. the current diagnosis is based on clinical examination, assessment of environmental exposures and patch testing. although the robustness of patch tests has long been established, this method can sometimes give inconclusive results, leading to problems in disease management. preliminary results indicate that the molecular analysis of patch-tests (pt) reactions could allow a more reliable diagnosis. importantly, this gene profiling approach may help to identify patients with false positive pt reactions, i.e. patients whose pt reactions did not show any "allergy signature". however, it remains to be demonstrated that the presence or absence of allergy biomarkers in pt lesions are indeed predictive of acd response in patients. the main objective is to describe the correlation between these molecular signatures and the reactivity of individuals when they are exposed to allergenic compounds under conditions of use (using roat test).


Eligibility criteria:
inclusion criteria: * patient, male or female, over 18 years of age. * patient with at least one positive/doubtful patch test reaction for nickel, limonene hydroperoxide and/or linalool hydroperoxide * patient agreeing to undergo skin biopsies and blood sampling * patient agreeing to non-identifying pictures being taken of lesions * patient available to carry out skin tests and their interpretation * patient affiliated to or benefiting from a social security regime * patient having been informed and having signed a written, free and informed consent. exclusion criteria: * patient with active dermatitis lesions on the forearm * patient with a history of allergic reaction to a local anesthetic product * patient with wound healing disorders (hypertrophic or keloids scars) * patient with hematological disorders * patient having topical treatments with corticosteroids or immunomodulators on the forearms during the 21 days prior to the start of the study * patient having had excessive exposure to ultraviolet during the 21 days prior to the start of the study. * patient on systemic corticosteroid therapy, immunosuppressants or biological therapy. * patient whose follow-up is impossible for reasons psychological or geographical. * patient taking part in another clinical study * protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * pregnant, breast-feeding or parturient woman
osimertinib combined with bevacizumab in patients with brain metastasis epidermal growth factor receptor (egfr) mutation positive metastatic non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: there is no positive data on osimertinib in the treatment of metastatic egfr mutation positive non-small-cell lung cancer (nsclc). the purpose of this study is to study osimertinib combined with bevacizumab in the management of patients with brain metastasis harboring egfr mutation.

lung cancer is one of the most common types of cancer and is the most common cause of death from cancer (almost 20 percent \[%\] of cancer deaths); nsclc accounts for 80% to 85% of lung cancers. the hypothesis is that osimertinib combined bevacizumab in patients with advanced nsclc patients with brain metastasis characterized by egfr mutations . efficacy assessments will include disease assessment, symptomatic progression and patient-reported outcome. safety assessments will include physical examinations, vital signs, electrocardiograms (ecgs), eastern cooperative oncology group (ecog) performance status and clinical safety laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis).

Eligibility criteria:
inclusion criteria: participant must have histologically or cytologically confirmed, metastatic, nonsquamous non-small cell lung cancer (nsclc) partipiant harboring primary epidermal growth factor receptor (egfr) exon 18-21 mutation and brain metastasis. participant must have measurable disease according to response evaluation criteria in solid tumors (recist) v1.1. participant must have eastern cooperative oncology group (ecog) performance status 0 or 1, or 2. participant must agree to genetic characterization of tumor status through the required pretreatment tumor biopsy (or submission of equivalent archival material), as well as baseline and periodic blood samples for analysis of tumor mutations in the bloodstream. a female participant of childbearing potential must have a negative serum or urine test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study. exclusion criteria: participant has history of spinal cord compression that has not been treated definitively with surgery or radiation. participant has a medical history of interstitial lung disease (ild), including drug-induced ild, or radiation pneumonitis. participant has a contraindication to the use osimertinib or bevacizumab.

Keywords: bronchial neoplasms egfr mutation osimertinib bevacizumab
effects on lipid metabolism of olive extracts rich in polyphenols

Conditions: Cholesterol; Metabolic Disorder; Metabolic Syndrome

Summary: this study is designed to determine whether a standardized intervention in the health center and based on hygienic dietary measures and physical exercise, supplemented with a polyphenol extract in patients, achieves a greater benefit in the reduction of ldl cholesterol in dyslipidemias in the short term.


Eligibility criteria:
inclusion criteria: * patients with dyslipidemia without the need for pharmacological treatment, but with annual follow-up of their dyslipidemia and with baseline ldl-cholesterol values. * patients to whom the annual analysis will be carried out for control of the lipid profile and who agree to postpone it during the month of the health education study. * patients who undergo hygienic-dietetic intervention and exercise. * patients willing to ingest the nutritional supplement of polyphenols that will be supplied to them. * signed the informed consent. exclusion criteria: * \<18 years old. * high cardiovascular risk. * with pharmacological treatment. * with some previous chronic disease. * with some allergy to the compounds of the product and placebo according to the technical specifications.
a study of enhancing drug prophylaxis of venous thromboembolism in chinese colorectal cancer surgery

Conditions: Colorectal Cancer

Summary: this project intends to conduct a multicenter, prospective, observational cohort study, aiming to explore the impact of the timing of pharmacological thromboprophylaxis initiation on postoperative bleeding risk and the effectiveness of venous thromboembolism (vte) prevention in chinese patients after colorectal cancer (crc) surgery. the research outcomes of this project could provide valuable insights for optimizing the prevention and management of vte after crc surgery.


Eligibility criteria:
inclusion criteria: - 1.age \> 18 years old; 2.the patient was diagnosed with colorectal cancer, and the ctmn stage was ct1-2, n0 or ct3, n0 or any ct, n1-2； 3.the patient was diagnosed with colorectal cancer and was able to receive radical surgery (laparoscopic or open surgery). the expected operation time was \>45 minutes, and the expected postoperative survival time was \>6 months. 4.the patient or guardian agrees to the study plan and signs the informed consent. exclusion criteria: * 1.renal insufficiency (crcl\ 3 times the upper limit of normal); 2.the patient was diagnosed with colorectal cancer with a ctmn stage of ct4 and/or local unresectable lesions. unresectable local recurrent lesions included: (1) extensive lateral pelvic wall invasion, (2) external iliac vascular involvement, (3) tumor invasion into the great sciatic notch, sciatic nerve invasion, and (4) invasion of the second sacrum level and above. 3.known allergy to low molecular weight heparin (lwmh), narcotic drugs or radiocontrast agents; 4.the presence of systemic hemorrhagic disease or bleeding tendency, such as active peptic ulcer, uncontrolled hypertension, cerebral thrombosis, cerebral hemorrhage or neurosurgical history within 6 months; 5.known brain metastases, endocarditis, or history of heparin-induced thrombocytopenia; 6.vte occurred within 3 months before surgery; 7.use heparin or oral anticoagulant therapy within 5 days before surgery; 8.women who are pregnant or breastfeeding; 9.any situation in which the investigator determines that the subject is not suitable for anticoagulant therapy.
a long-term extension study of wa19926 on the safety of tocilizumab (roactemra/actemra) in participants with early moderate to severe rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this open-label, single arm, multicenter long-term extension study will evaluate the safety and efficacy of tocilizumab (roactemra/actemra) in participants with moderate to severe rheumatoid arthritis who have completed the 104-week wa19926 core study. eligible participants will receive tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.


Eligibility criteria:
inclusion criteria: * adult participants, \>/= 18 years of age * participants who complete their last wa19926 core study visit (week 104) and who may benefit from study drug treatment, at baseline or later if they are in remission das28 at week 104 of wa19926, according to the investigator's assessment * no current or recent adverse event or laboratory finding preventing the use of the study drug dose of tocilizumab 8 mg/kg at baseline visit * women of childbearing potential must agree to use adequate contraception as defined by protocol during and up to 3 months after treatment exclusion criteria: * pregnant females * participants who have withdrawn prematurely from the wa19926 core study for any reason * treatment with any investigational agent or cell-depleting therapies since the last administration of study drug in wa19926 * treatment with an anti-tumor necrosis factor (tnf) or anti-interleukin (il) 1 agent, or a t-cell costimulation modulator since the last administration of study drug in wa19926 * immunization with a live/attenuated vaccine since the last administration of study drug in wa19926 * diagnosis since last wa19926 visit (week 104) of rheumatic autoimmune disease other than rheumatoid arthritis * diagnosis since last wa19926 visit (week 104) of inflammatory joint disease other than rheumatoid arthritis * history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, including tocilizumab and its excipients * evidence of severe uncontrolled concomitant disease or disorder * known active or history of recurrent infections * active tuberculosis requiring treatment in the previous 3 years * history of alcohol, drug or chemical abuse since inclusion in the wa19926 study
suprachoroidal hemorrhage associated with pars plana vitrectomy

Conditions: Suprachoroidal Hemorrhage (Diagnosis); Pars Plana Vitrectomy

Summary: to analyze the characteristics, related risk factors, and prognosis of suprachoroidal hemorrhage (sch) associated with pars plana vitrectomy (ppv).


Eligibility criteria:
inclusion criteria: * suprachoroidal hemorrhage associated with pars plana vitrectomy exclusion criteria: * patients with eye trauma-related suprachoroidal hemorrhage were excluded.
perioperative pregabalin in ureteroscopy: a pilot

Conditions: Nephrolithiasis; Urolithiasis; Perioperative/Postoperative Complications; Pain, Postoperative; Pain, Acute; Anesthesia; Urologic Diseases; Anesthesia Morbidity

Summary: the investigators propose a pilot clinical trial on the use of perioperative pregabalin in order to decrease ureteral stent related symptoms and decrease opioid usage after ureteroscopy with stent placement. patients undergoing ureteroscopy with stent placement will receive a single dose of 300 mg pregabalin po in the preoperative area. this work will assess safety and feasibility of studying this regimen at our institution, with the aim of performing a randomized, placebo-controlled, double-blinded study in the future.


Eligibility criteria:
subject population undergoing elective ureteroscopy with stent placement by dr. murray at university of missouri hospital and affiliated facilities subject inclusion age \>= 18 years subject exclusion * renal insufficiency (egfr \< 30 ml/minute/1.73 m2) * chronic indwelling ureteral stent * chronic opioid use * history of opioid abuse * chronic gabapentinoid use * plan for inpatient hospitalization * pregnancy * inability of the patient to consent for themselves in english * allergy to gabapentinoid * liver failure or hepatic dysfunction

Keywords: pregabalin perioperative medicine opioid sparing urolithiasis ureteroscopy
target planning for placement of dbs-electrodes and follow-up of the clinical efficacy of stimulation

Conditions: Movement Disorders; Epilepsy

Summary: deep brain stimulation (dbs) has been established as therapy for severe forms of parkinson's disease and other indications. a common target for stimulation is the subthalamic nucleus (stn). nevertheless, there is no agreement on the mechanisms how dbs leads to clinical improvement. the project aims to describe the variability of target coordinates in the patient group and to relate it to clinical outcome as documented in standardized questionaires. * trial with surgical intervention

deep brain stimulation (dbs) has been established as therapy for severe forms of parkinson's disease and other indications. a common target for stimulation is the subthalamic nucleus (stn). nevertheless, there is no agreement on the mechanisms how dbs leads to clinical improvement. the project aims to describe the variability of target coordinates in the patient group and to relate it to clinical outcome as documented in standardized questionaires.

Eligibility criteria:
inclusion criteria: * patients fullfill all criteria for implantation of deep brain stimulation (dbs) electrodes * patients are able to give informed written consent exclusion criteria: * patients do not their give informed written consent

Keywords: all indication for deep brain stimulation (dbs)
evaluation of laparoscopic internal retractor device

Conditions: Cholelithiasis

Summary: the purpose of this study is to determine the safety and efficacy of the endograb system which is an internal laparoscopic retractor device. this retractor device is inserted into the abdominal cavity through one of the 5 mm trocars and obviates the need for a separate dedicated trocar for retraction. therefore enables the reduction of the number of abdominal incisions in a laparoscopic operation.


Eligibility criteria:
inclusion criteria: * symptomatic cholelithiasis * age 18-60 * asa 1-2 * able to sign an informed consent exclusion criteria: * asa 3 or more * acute cholecystitis * choledocholithiasis * coagulation disorders * patients on blood thinners * use of steroids

Keywords: cholecystectomy cholecystectomy, laparoscopic laparoscopy
validation and standardisation of a pool of simplified evaluation aimed to the diagnoses of aphasic disorders and adapted to the patients suffering an acute phase of stroke

Conditions: Stroke

Summary: every year in france, from 100 000 to 145 000 people are affected by a stroke. 75% patients survived with aftereffects, in particular aphasic disorders. a sketch of a new tool called besta aiming to a rapid handover to the acute phase post stroke had been worked out. after a meeting, 13 multidisciplinary experts have discussed, adjusted and a new complete tool (besta) had been created in order to evaluate the different states of aphasia. the goal of this study is the validation and the standardization of this new besta tool.


Eligibility criteria:
inclusion criteria: patients with stroke: * every patient over 18, * admitted among neuro-vascular unit, * native french speaker, * the level of vigilance is satisfactory in order to allow a speech therapy test. healthy volunteers: * every volunteers over 18, * without any medical history of a stroke or any speech disorders, * native french speaker. exclusion criteria: patients with stroke and healthy volunteers : * dementia disease * psychiatric condition * non-equipped deafness * pregnant woman * patient with medical histories of stroke
the impact of metformin on the outcome of gouty arthritis in a cohort of egyptian gouty patients.

Conditions: Gouty Arthritis

Summary: objective: to study the impact of metformin on the outcome of gouty arthritis in a cohort of egyptian gouty patients, and to evaluate its effect on local joint inflammation, inflammatory cytokines (il-1β and il-6), and life quality. methods: a prospective randomized, single-blinded parallel randomized control study included 100 patients with active inflammatory gouty arthritis were randomized to receive metformin (1000mg/day) or placebo in addition to the traditional lines of treatment of gout. the clinical and laboratory data of the patients will be analyze at baseline, then after 3, and 6 months, with the assessment of gout disease activity, in addition, serum il-1β and il-6, the number of attacks per year, treatment satisfaction, quality of life, and disability index were evaluated at the 6th month from starting metformin and placebo therapy.

background: metformin has anti-inflammatory properties, as it suppresses the inflammatory process by down-regulating the transcription factor, nuclear factor kappa b (nf-kb), through amp-activated protein kinase (ampk)-dependent and independent pathways. objective: to study the impact of metformin on the outcome of gouty arthritis in a cohort of egyptian gouty patients, and to evaluate its effect on local joint inflammation, inflammatory cytokines (il-1β and il-6), and life quality. methods: a prospective randomized, single-blinded parallel randomized control study included 100 patients with active inflammatory gouty arthritis were randomized to receive metformin (1000mg/day) or placebo in addition to the traditional lines of treatment of gout. the clinical and laboratory data of the patients will be analyzed at baseline, then after 3, and 6 months, with the assessment of gout disease activity, in addition, serum il-1β and il-6, the number of attacks per year, treatment satisfaction, quality of life, and disability index were evaluated at the 6th month from starting metformin and placebo therapy.

Eligibility criteria:
inclusion criteria: * gouty patients who fulfilled the american college of rheumatology clinical criteria. * gouty patients with active inflammatory arthritis. exclusion criteria: * patients with any type of inflammatory arthritis. * patients with systemic disease as diabetes, hypertension, * patients with hyperlipidemia, coronary artery disease, * patients with renal or hepatic insults, * pregnant and lactating females
effectiveness of supplementary feeding during infection among moderately malnourished children

Conditions: Malnutrition; Infection

Summary: the purpose of this study is to determine whether an outpatient-based strategy of short-term, ready to use supplementary food (rusf) among moderately malnourished children with acute infections achieves greater improvement in anthropometric measurements of wasting than usual diet.

under nutrition is a contributing factor to at least a third of child deaths. whilst severe malnutrition has the highest mortality risk, most malnutrition-related deaths are thought to be related to mild-moderate malnutrition.this is because moderate malnutrition is common, it directly increases the risk of death from common infectious diseases and may progress to severe malnutrition. malnutrition may arise from poverty, food insecurity or inadequate nutrition being offered, and may begin early in life. malnutrition is exacerbated by the multiple effects of infectious diseases such as gastroenteritis, pneumonia, malaria or hiv. all these common infections are associated with net protein loss with diversion of essential amino acids to producing acute phase and immune response proteins. fever is associated with an increased resting energy expenditure of 7 to 13% per degree centigrade. activation of inflammatory cascades also causes reduced appetite and loss of lean tissue and fat. acute infection is therefore associated with growth faltering, resulting in a vicious cycle. acute infection is therefore a potential target for intervention to interrupt the vicious cycle between malnutrition and infection in children. this study aims to evaluate a strategy of giving short-term rusf as a supplement to usual diet at home, without daily observed feeding, administered through existing health services at kilifi district hospital, kenya. rusf has a very low moisture content and is essentially a lipid-enveloped paste, it is microbiologically stable with a long shelf life at tropical temperatures and preserves delicate micronutrients such as vitamin a.

Eligibility criteria:
inclusion criteria: * age 6 months to 5 years * mid-upper arm circumference (muac) less than 12.5 cm * resident in the kilifi demographic surveillance (dss) area * presentation with acute (\<5 days) illness including respiratory infection, malaria, diarrhoeal disease or other acute infection. * if admitted, admission of \<5 days, recruited at discharge. exclusion criteria: * severe malnutrition (whz score \< -3 or kwashiorkor) * requiring admission to hospital in the opinion of clinician * known allergy to maize, soya, sorghum, milk or any rusf components. * consent declined * underlying condition precluding assessment or inclusion * any other reason why the consenting investigator thinks it is not appropriate for them to take part.

Keywords: supplementary feeding moderate malnutrition acute infection developing country children